SOMATOSTATIN RECEPTOR IMAGING IN SMALL-CELL LUNG-CANCER USING IN-111 DTPA-OCTREOTIDE - A PRELIMINARY-STUDY

被引：28

作者：

MAINI, CL ^{[1
]}

TOFANI, A ^{[1
]}

VENTURO, I ^{[1
]}

PIGORINI, F ^{[1
]}

SCIUTO, R ^{[1
]}

SEMPREBENE, A ^{[1
]}

BONI, S ^{[1
]}

GIUNTA, S ^{[1
]}

LOPEZ, M ^{[1
]}

机构：

[1] REGINA ELENA INST CANC RES,DEPT NUCL MED,ROME,ITALY

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1993年 / 14卷 / 11期

关键词：

D O I：

10.1097/00006231-199311000-00005

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Small cell lung cancer is a common and aggressive disease. Combined multiagent chemotherapy and radiotherapy can improve short-term prognosis, but long-term prognosis remains dim. Somatostatin receptors have been identified on the cellular surface of subsets of this cancer and may be associated with less aggressive evolution. Moreover, medical therapy with somatostatin analogues holds promise for neoplastic growth control. Planar scintigraphy has been performed in 15 patients with histologically proven small cell lung cancer at 4 and 24 h after the intravenous (i.v.) injection of 185 MBq In-111-octreotide (Octreoscan, BYK-Gulden). No short-term adverse effects were recorded; tumour uptake of the radiopharmaceutical was observed in 13 patients at 4 h and in 12 patients at 24 h suggesting more extensive disease than apparent by computed tomography (CT). It is highly likely that the 24 h uptake reflects the presence of somatostatin receptors on the tumour. Previous chemotherapy does not seem to play a key role in tumour visualization. In-111-octreotide is a suitable radiopharmaceutical for in vivo evaluation of somatostatin receptor status of small cell lung cancer. Quantitative scintigraphic methods are needed to investigate nonspecific binding and receptor kinetics.

引用

页码：962 / 968

页数：7

共 46 条

[1]

Andrews J.L., Bloom S., Balogh K., Beamis J.F., Lung cancer in women, Cancer, 55, pp. 2894-2898, (1985)

[2]

Chute C.G., Greenberg E.R., Baron J., Korson R., Baker J., Yates J., Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont, Cancer, 56, pp. 2017-2111, (1985)

[3]

Livingston R.B., Moore T.N., Heilbrun L., Small-cell carcinoma of the lung: Combined chemotherapy and radiation, Ann Lntl Med, 88, pp. 194-199, (1978)

[4]

Havemann K., Wolf M., Holle R., Alternating versus sequential chemotherapy in small cell lung cancer, Cancer, 59, pp. 1072-1082, (1987)

[5]

Wolf M., Havemann K., Holle R., Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in smallcell lung cancer: A multicenter German randomized trial, J Clin Oncol, 5, pp. 1980-1989, (1987)

[6]

Davis S., Wright P.W., Schulman S.F., Scholes D., Thoming D., Hammar S., Long-term survival in small-cell carcinoma of the lung: A population experience, J Clin Oncol, 3, pp. 80-91, (1985)

[7]

Osterlind K., Hansen H.H., Hansen M., Dombernowsky P., Erson P.K., Long term disease-free survival in smallcell carcinoma: A study of clinical determinants, J Clin Oncol, 4, pp. 1307-1313, (1986)

[8]

Rosti G., Donadio M., Crino L., Figoli F., Bisagni G., Leoni M., Clerici M., Marangolo M., Long survivors in small cell lung cancer (SCLC): Italian report on 3245 cases, Twenty- Seventh Annual Meeting of American Society of Clinical Oncology, 10, (1991)

[9]

Johnston-Early A., Cohen M.K., Minna J.D., Smoking abstinence and small cell lung cancer surviva, J M Med Asso, 24, (1980)

[10]

Osterlind K., Andersen PK. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation, Cancer Res, 46, pp. 4189-4194, (1986)

← 1 2 3 4 5 →